Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Key Points

• Main finding shows acquired resistance mechanisms to KRASG12C-EGFR inhibition in colorectal cancer.
• Key evidence demonstrates drug withdrawal responses in resistant cells, indicating the importance of treatment strategies.
• Approach involves analyzing patient data and cell line models to understand resistance patterns.
• Significance lies in improving therapeutic strategies for colorectal cancer patients with KRASG12C mutations.